Pandemi Dönemi Öncesinde Türkiye'de İnsülin ve Glukagon Benzeri Peptid-1 Analog Satışlarının Değerlendirilmesi; Önümüzdeki Yıllar İçin Projeksiyon: Bir Pazar Analiz Çalışması

Yıl 2023, , 48 - 54, 16.03.2023

İsmail Mert Vural , Çağıl Önal Sis Kemal Gökhan Ulusoy , Oğuzhan Yıldız

https://doi.org/10.31832/smj.1021311

Öz

Bu çalışmada, Türkiye'deki insülin preparatları ve glukagon benzeri peptid-1 (Glp-1) analoglarının terapötik kategorilerine göre kutu satış trendlerini değerlendirmek amaçlanmıştır. Ayrıca bu ilaçların önümüzdeki yıllardaki satış trendlerini de yansıtılması hedeflenmiştir. Covid-19 pandemisi öncesi verileri analiz edilmiş ve bu verilere dayanarak tahminlerde bulunulmuştur. Bu çalışmada, 4 terapötik gruptaki insülin preparatlarının (hızlı/kısa etkili, orta etkili, premiks, uzun etkili) ve Glp-1 analoglarının perakende ve hastane kutu satışlarını analiz edilmiştir. İncelenen dönemde insülin preparatlarının toplam kutu satışlarının %13,30 oranında arttığı saptanmıştır. Hızlı/kısa etkili ve uzun etkili insülin kutusu satışları azalan artış trendi ile artarken, orta etkili ve premiks insülin kutu satışları azalmıştır. Glp-1 analog satışları bu dönemde hızla artmıştır. Diyabet tedavisi için Türkiye pazarına yeni ilaç grupları ve etken maddeler girmektedir. Bu yeni ilaçların diyabet tedavisinde daha yaygın olarak kullanılması daha az insülin kullanımına neden olabilir. Ayrıca gelecekte yapılacak çalışmalarda pandeminin kronik hastalıkların tedavisinde kullanılan ilaçlara erişim üzerindeki etkisinin değerlendirilmesi faydalı olacaktır.

Anahtar Kelimeler

Diyabetes Mellitüs, İnsülin satışları, ; Glukagon benzeri peptid-1 analog satışları

Evaluation of Insulin and Glucagon-Like Peptide-1 Analog Sales in Turkey Before the Pandemic Period; Projection for Upcoming Years: A Market Analysis Study

Öz

This study was designed to evaluate the box sale trends of insulin preparations and glucagon-like peptide-1 (Glp-1) analogs by their therapeutic categories in Turkey. Also, we aimed to project sale trends of these pharmaceuticals in next years. We analyzed the data before the covid-19 pandemic and made predictions based on these data. This study analyzed retail and hospital box sales of insulin preparations from 4 therapeutic categories (fast/short-acting, intermediate-acting, premix, long-acting) and Glp-1 analogs. Total box sales of the insulin preparations were increased by %13,30 in the period examined. While fast/short-acting and long-acting insulin box sales increased with a decreasing upward trend, intermediate-acting and premix insulin box sales decreased. Glp-1 analog sales increased rapidly in this period. Currently, newer pharmaceuticals have been entering Turkish market for diabetes treatment. Less insulin might be required if newer pharmaceuticals are more widely available in diabetes treatment. Also it will be useful to evaluate the effect of the pandemic on access to pharmaceuticals used in the treatment of chronic diseases in future studies.

Anahtar Kelimeler

Diabetes mellitus, Insulin sales, Glucagon-like peptide-1 analog sales

Kaynakça

• 1. Satman I, Omer B, Tutuncu Y, Kalaca S, Gedik S, Dinccag N, Karsidag K, Genc S, Telci A, Canbaz B, Turker F, Yilmaz T, Cakir B, Tuomilehto. Twelve-year trends in the prevalence and risk factors of diabetes and pre-diabetes in Turkish adults. Eur J Epidemiol 2013; 28:169-180.
• 2. International Diabetes Federation. IDF diabetes atlas, 9th edn. International Diabetes Federation, 2019, Brussels, Belgium. https ://diabetesatlas.org/en/resources/. Accessed 3 Feb 2020.
• 3. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2017; 40 (Suppl.1): S1–135.
• 4. Gardner DG, Shoback D Greenspan’s Basic & Clinical Endocrinology, 10th edn. McGraw-Hill Education, China. 2018
• 5. Singh SR, Ahmad F, Lal A, Yu C, Bai Z, Bennett H. Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis. CMAJ. 2009; 17;180(4):385-97.
• 6. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012; 55:1577–1596.
• 7. National Collaborating Centre for Chronic Conditions. Type 2 diabetes: a national clinical guideline for management in primary and secondary care (update). Royal College of Physicians, London, England. 2008
• 8. Scottish Intercollegiate Guidelines Network. Management of diabetes. A national clinical guideline. Scottish Intercollegiate Guidelines Network (SIGN), Edinburgh, Scotland. 2010
• 9. Turkish Endocrinology and Metabolism Society. Guideline of Diagnosis, Treatment and Follow-up of Diabetes Mellitus and Complications. Ankara, Turkey (in Turkish). 2014
• 10. Tinahones F, Gross J, Onaca A, Cleall S, Rodríguez A. Insulin lispro low mixture twice daily versus basal insulin glargine once daily and prandial insulin lispro once daily in patients with type 2 diabetes requiring insulin intensification: a randomized phase IV trial. Diabetes Obes Metab, 2014; 16 (10):963- 970.
• 11. Garg SK, Gottlieb PA, Hisatomi ME, Souza A, Walker A, Izuora K, Chase HP. Improved glycemic control without an increase in severe hypoglycemic episodes in intensively treated patients with type 1 diabetes receiving morning, evening, or split dose insulin glargine. Diabetes Res Clin Pract 2004; 66 (1):49-56.
• 12. National Institute for Health and Care Excellence. Diabetes (type 1 and type 2) in children and young people: diagnosis and management. Clinical Guidelines, London/England. 2015
• 13. Frias PF, Frias JP. New Basal Insulins: a Clinical Perspective of Their Use in the Treatment of Type 2 Diabetes and Novel Treatment Options Beyond Basal Insulin. Current Diabetes Report. 2017; 17(10):91.
• 14. Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, Dagogo-Jack S, DeFronzo RA, Einhorn D, Fonseca VA, Garber JR, Garvey WT, Grunberger G, Handelsman Y, Hirsch IB, Jellinger PS, McGill JB, Mechanick JI, Rosenblit PD, Umpierrez GE. Consensus statement by the Amerıcan Association of Clinical Endocrinologists and Amerıcan College of Endocrinology on the comprehensive type 2 diabetes management algorithm– 2018 executive summary. Endocr Pract. 2018; 24:91-120.
• 15. Basu S, Yudkin JS, Kehlenbrink S, Davies JI, Lipska KJ, Sussman JB, Beran D. Estimation of global insulin use for type 2 diabetes, 2018–30: a microsimulation analysis. The Lancet Diabetes & Endocrinology 2019; 7:25-33.
• 16. Cefalu WT, Dawes DE, Gavlak G, Goldman D, Herman WH, Van Nuys K, Powers AC, Taylor SI, Yatvin AL, on behalf of the Insulin Access and Affordability Working Group. Insulin Access and Affordability Working Group: Conclusions and Recommendations. Diabetes Care 2018; 41(6): 1299-1311.
• 17. Xu Y, Gomes T, Mamdani MM, Juurlink DN, Cadarette SM, Tadrous M. Analysis of Trends in Insulin Utilization and Spending Across Canada From 2010 to 2015. Can J Diabetes. 2019; 43(3):179-185.
• 18. Griffiths WE, Hill CR, Judge GG. Learning and Practicing Econometrics. John Wiley and Sons Inc, New York. 1992
• 19. Enders W. Applied Time Series Analysis. John Wiley and Sons Inc, New York. 1995
• 20. Ministry of Health. Health Statistics Yearbook 2017. Republic of Turkey Ministry of Health, Ankara, Turkey. 2019
• 21. Kaplan W, Mathers C. The World Medicines Situation 2011, Global Health Trends: Global Burden of Disease and Pharmaceutical Needs, World Health Organization, Geneva, Switzerland. 2011
• 22. Turkish Statistical Institute (2013), Population projections, 2013–2075 (news bulletin). http://www.turkstat.gov.tr/PreHaberBultenleri.do?id=15844. Accessed December 23, 2019 (in Turkish).
• 23. Association AD. Economic costs of diabetes in the U.S. in 2017. Diabetes Care. 2018; 41(5):917–28.
• 24. Peters ML, Huisman EL, Schoonen M, Wolffenbuttel BHR. The current total economic burden of diabetes mellitus in the Netherlands. Neth J Med. 2017; 75(7):281–97.
• 25. Marcellusi, A., Viti, R., Mecozzi, A., Mennini FS. The direct and indirect cost of diabetes in Italy: a prevalence probabilistic approach. Eur J Health Econ. 2016; 17:139–147.
• 26. International Diabetes Federation. Recommendations for Managing Type 2 Diabetes In Primary Care. 2017
• 27. Wilke T, Picker N, Mueller S, Geier S, Foersch J, Aberle J, MartinS, Riedl M, Gabler M. Real-world insulin therapy in German type 2 diabetes mellitus patients: patient characteristics, treatment patterns, and insulin dosage. Diabetes Metab Syndr Obes. 2019; 12: 1225–1237.
• 28. EvaluatePharma® (2019) World Preview 2019, Outlook to 2024. 12th Edition https://info.evaluate.com/rs/607-YGS-364/images/EvaluatePharma_World_Preview_2019.pdf Accessed 6 Jan 2020 29. Gursoz H, Vural IM. Cost Evaluation and Budget Impact Analysis on Fixed Dose Combined Drugs Used in Chronic Diseases. Ministry of Health, Turkish Medicines and Medical Devices Agency, Ankara. 2016 (in Turkish).
• 30. Blind E, Janssen H, Dunder K, de Graeff PA. The European Medicines Agency's approval of new medicines for type 2 diabetes. Diabetes Obes Metab. 2018: 20(9):2059-2063.
• 31. Tieu C, Lucas EJ, DePaola M, Rosman L, Alexander GC. Efficacy and safety of biosimilar insulins compared to their reference products: A systematic review. PLoS One. 2018; 13(4):e0195012.
• 32. Doğukan MN, Köselerli R, Özcan, O, Öztürk P. Diabetes with Social Security Institution Perspective, International Diabetes Leaders’ Summit, Turkey 2013. ÖSGK, Ankara 2013 (in Turkish).
• 33. Chatterjee S., Davies MJ, Khunti K. What have we learnt from “real world” data, observational studies and meta‐analyses. Diabetes Obesity Metabolism. 20, IssueS1 Supplement: Maximising the Clinical Benefit of Incretin Therapies: Diabetes and Beyond 2018; 47-58.
• 34. Fadini GP, Frison V, Rigato M, Morieri ML, Simioni N, Tadiotto F, D'Ambrosio M, Paccagnella A, Lapolla A, Avogaro A. (2019) Trend 2010-2018 in the clinical use of GLP-1 receptor agonists for the treatment of type 2 diabetes in routine clinical practice: an observational study from Northeast Italy. Acta Diabetol. doi: 10.1007/s00592-019-01445-z. [Epub ahead of print]
• 35. Mordor Intelligence (2019) Glucagon-like peptide-1 (GLP-1) agonists market-growth, trends, and forecast (2020 - 2025). https://www.mordorintelligence.com/industry-reports/glucagon-like-peptide-1-agonists-market; Accessed 5 Feb 2020.
• 36. P&T Community. North America Glucagon like Peptide - 1 Agonists Market 2019-2024 by Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide) & Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca) https://www.ptcommunity.com/wire/north-america-glucagon-peptide-1-agonists-market-2019-2024-drug-exenatide-liraglutide; Accessed 5 Feb 2020.
• 37. Peter PR, Lupsa BC. Personalized Management of Type 2 Diabetes. Current Diabetes Reports 2019; 19(11):115. doi: 10.1007/s11892-019-1244-0.